Dr Lukas Burkhardt has been appointed to the management board of Gerresheimer effective 1 January. Lukas Burkhardt will assume responsibility for the primary packaging glass division. Chairman of the ...

Mankind Pharma has entered into a partnership with Innovent Biologics for licensing and commercialising Sintilimab for cancer in India.

A $4.75m grant will support the development of EIS-12656, which is being studied alone and in combination with PARP inhibitors.

StemVacs-V is under clinical development by Res Nova Bio and currently in Phase II for Metastatic Breast Cancer.

Gene Therapy to Target GD2 for Oncology is under clinical development by Bristol-Myers Squibb and currently in Phase I for Osteosarcoma.

Tricaprilin is under clinical development by Cerecin and currently in Phase II for Infantile Spasm (West Syndrome).

Nelivaptan (NB-415, SSR-149415) is under development for the treatment of depression including major depressive disorder (MDD). The drug candidate targets vasopressin receptor 1B ( (V1bR). It is ...

CG-0255 is under clinical development by Shanghai CureGene Pharmaceutical and currently in Phase II for Acute Coronary Syndrome.

CR-4056 is under clinical development by Rottapharm Biotech and currently in Phase II for Osteoarthritis Pain.

Prexigebersen is under clinical development by Bio-Path and currently in Phase II for Relapsed Acute Myeloid Leukemia.

CTEcells is under clinical development by CTE Biologics and currently in Phase II for Chronic Traumatic Encephalopathy (CTE).

RioDerm-002 is under clinical development by Rion and currently in Phase I for Radiation Injury. According to GlobalData, Phase I drugs for Radiation Injury does not have sufficient historical data to ...